| 101 | 11346684 | Neoadjuvant therapy in breast cancer: can we define its role? | Oncologist | 2001 |
1 |
| 102 | 11384110 | Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. | Br J Cancer | 2001 Jun 1 |
7 |
| 103 | 11389879 | Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. | Biochem Pharmacol | 2001 Jul 15 |
3 |
| 104 | 11391617 | Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. | Int J Cancer | 2001 Jul 1 |
3 |
| 105 | 11400119 | Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. | Int J Cancer | 2001 Jul 20 |
4 |
| 106 | 11408509 | Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. | J Clin Oncol | 2001 Jun 15 |
2 |
| 107 | 11419031 | Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents. | Cancer J | 2001 May-Jun |
1 |
| 108 | 11488523 | Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. | Cancer Chemother Pharmacol | 2001 Jul |
3 |
| 109 | 11521725 | Ongoing trials with trastuzumab in metastatic breast cancer. | Ann Oncol | 2001 |
1 |
| 110 | 11549208 | Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. | Eur J Clin Pharmacol | 2001 Jul |
6 |
| 111 | 11561777 | Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. | Cancer Chemother Pharmacol | 2001 Aug |
9 |
| 112 | 11583191 | Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. | Ann Oncol | 2001 Aug |
1 |
| 113 | 11685722 | Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. | Semin Oncol | 2001 Aug |
3 |
| 114 | 11685723 | Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. | Semin Oncol | 2001 Aug |
1 |
| 115 | 11685725 | Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. | Semin Oncol | 2001 Aug |
1 |
| 116 | 11685728 | Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. | Semin Oncol | 2001 Aug |
1 |
| 117 | 11685729 | Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. | Semin Oncol | 2001 Aug |
1 |
| 118 | 11685730 | Docetaxel and exisulind in hormone-refractory prostate cancer. | Semin Oncol | 2001 Aug |
1 |
| 119 | 11685731 | A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. | Semin Oncol | 2001 Aug |
1 |
| 120 | 11685732 | Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. | Semin Oncol | 2001 Aug |
1 |
| 121 | 11685733 | Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. | Semin Oncol | 2001 Aug |
1 |
| 122 | 11694787 | Interaction between Herceptin and taxanes. | Oncology | 2001 |
1 |
| 123 | 11697840 | Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. | Ann Oncol | 2001 Sep |
1 |
| 124 | 11710628 | Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. | Cancer Chemother Pharmacol | 2001 Oct |
3 |
| 125 | 11713371 | Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. | Mol Med | 2001 Oct |
1 |
| 126 | 11724283 | Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. | Anticancer Res | 2001 Jul-Aug |
2 |
| 127 | 11726273 | Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. | J Biochem | 2001 Dec |
1 |
| 128 | 11770832 | Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. | Int J Clin Pharmacol Ther | 2001 Dec |
1 |
| 129 | 11774254 | Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. | Int J Cancer | 2002 Jan 1 |
6 |
| 130 | 11778270 | [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity]. | Zhonghua Zhong Liu Za Zhi | 2000 Sep |
4 |
| 131 | 11788897 | Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. | Int J Oncol | 2002 Feb |
1 |
| 132 | 11839680 | MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. | Clin Cancer Res | 2002 Feb |
3 |
| 133 | 11852999 | Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. | Cancer Invest | 2002 |
1 |
| 134 | 11872346 | C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. | Eur J Cancer | 2002 Mar |
1 |
| 135 | 11875716 | Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2. | Br J Cancer | 2002 Feb 1 |
12 |
| 136 | 11895918 | Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. | Clin Cancer Res | 2002 Mar |
3 |
| 137 | 11899413 | Platinum compounds in the treatment of advanced breast cancer. | Clin Breast Cancer | 2001 Oct |
1 |
| 138 | 11901098 | Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. | Drug Metab Dispos | 2002 Apr |
5 |
| 139 | 11919237 | Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. | J Clin Oncol | 2002 Apr 1 |
3 |
| 140 | 11929841 | Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. | Cancer Res | 2002 Apr 1 |
1 |
| 141 | 11992642 | Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. | Biochem Pharmacol | 2002 Feb 15 |
4 |
| 142 | 12008197 | Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. | Eur J Cancer | 2002 May |
1 |
| 143 | 12016869 | [Synthesis and cytotoxicity of the new taxoids]. | Yao Xue Xue Bao | 1998 Sep |
1 |
| 144 | 12085250 | Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. | Br J Cancer | 2002 Jul 1 |
14 |
| 145 | 12090045 | [A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy]. | Gan To Kagaku Ryoho | 2002 Jun |
1 |
| 146 | 12097284 | Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. | Cancer Res | 2002 Jul 1 |
1 |
| 147 | 12108894 | The current status of docetaxel for metastatic breast cancer. | Oncology (Williston Park) | 2002 Jun |
2 |
| 148 | 12108896 | Primary chemotherapy with docetaxel for the management of breast cancer. | Oncology (Williston Park) | 2002 Jun |
1 |
| 149 | 12108899 | Docetaxel in the integrated management of prostate cancer. Current applications and future promise. | Oncology (Williston Park) | 2002 Jun |
1 |
| 150 | 12113067 | EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer. | Expert Rev Anticancer Ther | 2002 Feb |
2 |